Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy

Authors

Institutions

Publication Details

Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2025-05-07
DOI
https://doi.org/10.1080/14737167.2025.2499720
Primary Topic
Neurogenetic and Muscular Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy

Yueyang Huang, Zhe Huang, Hongmei Yuan
Expert Review of Pharmacoeconomics & Outcomes Research
Neurogenetic and Muscular Disorders Research
article

Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy

Yueyang Huang, Zhe Huang, Hongmei Yuan
article en

Abstract

No abstract available for this paper.
Expert Review of Pharmacoeconomics & Outcomes ResearchVol. 25(6)
Shenyang Pharmaceutical University (CN)
Zero hunger
Openalex Percentile: Top 86%
Neurogenetic and Muscular Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy — Yueyang Huang, Zhe Huang, et al. · Expert Review of Pharmacoeconomics & Outcomes Research (2025) | TGRS Research Map | TGRS